Agilent Technologies, Inc.

A

NYSE; business equipment; SIC 3826, Laboratory Analytical Instruments; CIK 0001090872

B/C

on the B/C boundary of 494 graded peers in business equipm...

rank 188 of 494; percentile 37.9; sampling error 2.2 points; lower is stronger



B/C, the elk



Scoreboard	
Profitability	C percentile 46.9
Solvency	B percentile 35.1
Growth and financing	C percentile 52.7
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $12.7B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	13 of 14
Graded from	filings received through Dec 22, 2025 329 days before the rescan; latest periodic filing 10-Q received Sep 1, 2026
Last close	$173.91 2026-11-13; market equity $49.0B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Dec 22, 2025

Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. In November 2024, we announced a change in our organizational structure to support our market-focused, customer-centric strategy. Our former Diagnostics and Genomics segment combined with our liquid chromatography and liquid chromatography mass spectrometry instrument platforms to form our new Life Sciences and Diagnostics Markets segment.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 46.9						
Gross profitability	28.6%	28.7%		47.0	550	2025-10-31
Return on invested capital	16.9%	11.2%		32.1	132	2025-10-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(2.1%)	(7.3%)	79.2	613	2025-10-31
Gross margin stability, five years	1.4 pts	2.3 pts	29.5	422	2025-10-31
Solvency, sleeve percentile 35.1					
Twelve-month failure probability	not computable	0.05%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	3.48	2.21	32.1	561	2025-10-31
Net debt to EBITDA	0.71x	1.09x	38.6	146	2025-10-31
Interest coverage	13.21x	3.77x	18.6	87	2025-10-31
Current ratio	1.96x	2.01x	51.0	658	2025-10-31
Growth and financing, sleeve percentile 52.7					
Revenue growth, three-year compound	0.5%	6.4%	67.4	531	2025-10-31
Free cash flow growth, three-year compound	4.1%	17.7%	71.9	264	2025-10-31
Reinvestment rate	22.5%	15.1%	48.6	223	2025-10-31
Asset growth, three years	6.5%	5.2%	43.5	555	2025-10-31
Net share issuance, one year	(0.7%)	0.5%	32.3	406	2025-12-10

Among 494 peers

business equipment; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
183	Plexus Corp. (PLXS)	36.9	B	fortress balance sheet
184	Legalzoom.Com, Inc. (LZ)	37.1	B	
185	Blackline, Inc. (BL)	37.3	B	
186	Intest Corp. (INTT)	37.5	B	fortress balance sheet
187	R F Industries Ltd. (RFIL)	37.7	B	
188	Agilent Technologies, Inc. (A)	37.9	B/C	
189	indie Semiconductor, Inc. (INDI)	38.1	B/C	
190	10x Genomics, Inc. (TXG)	38.3	B/C	fortress balance sheet
191	Clearfield, Inc. (CLFD)	38.5	B/C	fortress balance sheet
192	Silicon Laboratories Inc. (SLAB)	38.7	B/C	
193	Factset Research Systems Inc. (FDS)	38.9	B/C	

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	18.3%	(2.0%)	64
Distance from 52-week high	(4.1%)	(35.0%)	90
EBIT to enterprise value	2.9%	1.7%	60
Free cash flow yield	2.3%	2.8%	43
Book value to price	0.15	0.27	30
Sales to price	0.14	0.32	26
Composite equity issuance, five years	(12.5%)	4.4%	23
Relative strength against the sector, log excess return	(0.10)	(0.29)	64

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-10-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$1.8B
Operating cash flow, four quarters	$1.6B
Months of runway	not finite
Days since last periodic filing	76 (10-Q received Sep 1, 2026)
Median daily dollar volume, 63 sessions	$384.3M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$6.9B	2025-10-31	2025-12-22	10-K	25-000087
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$3.3B	2025-10-31	2025-12-22	10-K	25-000087
3	assets	us-gaap:Assets	$12.7B	2025-10-31	2025-12-22	10-K	25-000087
4	operating income	us-gaap:OperatingIncomeLoss	$1.5B	2025-10-31	2025-12-22	10-K	25-000087
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$1.4B	2025-10-31	2025-12-22	10-K	25-000087
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$132.0M	2025-10-31	2025-12-22	10-K	25-000087
7	total debt	us-gaap:LongTermDebt	$3.0B	2025-10-31	2025-12-22	10-K	25-000087
8	book equity	us-gaap:StockholdersEquity	$6.7B	2025-10-31	2025-12-22	10-K	25-000087
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.8B	2025-10-31	2025-12-22	10-K	25-000087
10	total debt	us-gaap:LongTermDebt	$3.3B	2024-10-31	2025-12-22	10-K	25-000087
11	book equity	us-gaap:StockholdersEquity	$5.9B	2024-10-31	2025-12-22	10-K	25-000087
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.3B	2024-10-31	2025-12-22	10-K	25-000087
13	net income	us-gaap:NetIncomeLoss	$1.3B	2025-10-31	2025-12-22	10-K	25-000087
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.6B	2025-10-31	2025-12-22	10-K	25-000087
15	assets	us-gaap:Assets	$11.8B	2024-10-31	2025-12-22	10-K	25-000087
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$6.5B	2024-10-31	2025-12-22	10-K	25-000087
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$3.0B	2024-10-31	2025-12-22	10-K	25-000087
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$6.8B	2023-10-31	2025-12-22	10-K	25-000087
19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$3.4B	2023-10-31	2025-12-22	10-K	25-000087
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$6.8B	2022-10-31	2024-12-20	10-K	24-000049
21	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$3.1B	2022-10-31	2024-12-20	10-K	24-000049
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$6.3B	2021-10-31	2023-12-20	10-K	23-000020
23	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$2.9B	2021-10-31	2023-12-20	10-K	23-000020
24	current assets	us-gaap:AssetsCurrent	$4.6B	2025-10-31	2025-12-22	10-K	25-000087
25	current liabilities	us-gaap:LiabilitiesCurrent	$2.3B	2025-10-31	2025-12-22	10-K	25-000087
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$1.4B	2025-10-31	2025-12-22	10-K	25-000087
27	liabilities	us-gaap:Liabilities	$6.0B	2025-10-31	2025-12-22	10-K	25-000087
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$288.0M	2025-10-31	2025-12-22	10-K	25-000087
29	interest expense	us-gaap:InterestExpense	$112.0M	2025-10-31	2025-12-22	10-K	25-000087
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$407.0M	2025-10-31	2025-12-22	10-K	25-000087
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.8B	2024-10-31	2025-12-22	10-K	25-000087

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$378.0M	2024-10-31	2025-12-22	10-K	25-000087
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.8B	2023-10-31	2025-12-22	10-K	25-000087
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$298.0M	2023-10-31	2025-12-22	10-K	25-000087
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.3B	2022-10-31	2024-12-20	10-K	24-000049
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$291.0M	2022-10-31	2024-12-20	10-K	24-000049
37	current assets	us-gaap:AssetsCurrent	$4.0B	2024-10-31	2025-12-22	10-K	25-000087
38	current liabilities	us-gaap:LiabilitiesCurrent	$1.9B	2024-10-31	2025-12-22	10-K	25-000087
39	assets	us-gaap:Assets	$10.8B	2023-10-31	2024-12-20	10-K	24-000049
40	assets	us-gaap:Assets	$10.5B	2022-10-31	2023-12-20	10-K	23-000020
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	283,498,871	2025-12-10	2025-12-22	10-K	25-000087
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	285,595,302	2024-12-09	2024-12-20	10-K	24-000049

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.